Compare AbbVie Inc (ABBV) vs GSK plc (GSK) Price & Performance

AbbVie IncTrade

GSK plcTrade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs GSK plc — how do they compare? AbbVie Inc trades at $248.26 (market cap $441.94B), while GSK plc trades at $50.26 (market cap $102.60B). The key difference: AbbVie Inc is far larger — about 4.3× GSK plc's market cap, and GSK plc pays the higher dividend (3.57%). Which is the better fit depends on your goals.

	ABBV	GSK
Market Cap	$441.94B	$102.60B
Sector	Health	Health
52-Week High	$263.58	$61.18
52-Week Low	$197.38	$38.22
Enterprise Value	$506.19B	$123.04B
Dividend Yield	2.77%	3.57%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.

Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.

GSK plc

GSK trades at $52.16, down 1.51% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates, and announced a $2.52 billion cost-saving plan to accelerate drug development. Revenue growth remains steady, with 2025 revenue at $32.67 billion and net income of $5.72 billion, though profit margins have fluctuated in recent years.

Outlook is positive with continued earnings beats and strategic investments, but risks include competitive pressures and regulatory uncertainties. Analyst sentiment is mixed with 31% buy ratings, 55% hold, and 14% sell, reflecting cautious optimism amid execution risks and market volatility.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

ABBV

Fidelity Dividend ETF's payout is safe but not ideal for steady income due to variable quarterly dividends.24/7 Wall Street · 1 day agoNeutral Two Dividend Aristocrats outperformed the market while two lagged; three new picks show promising dividend growth.24/7 Wall Street · 2 days agoNeutral Healthcare sector leads S&P 500 gains over 3 months with key pharma stocks showing strong innovation and income potential.24/7 Wall Street · 2 days agoBullish View details →

GSK

Trump orders splitting MMR vaccine into three shots despite no scientific support and expert criticism.CNBC · 1 day agoBearish Theravance Biopharma to be acquired by Zymeworks in H2 2026; Q2 revenue up 11% on YUPELRI growth and cost cuts.PRNewsWire · 2 days agoBullish View details →

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

About GSK plc

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.